TIDMOPTI
RNS Number : 6368F
OptiBiotix Health PLC
18 November 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
License and supply agreement with Genuine Health
LP(LDL) (R) license for Canada and USA
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that its wholly-owned
subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has granted a
non-exclusive LP(LDL) (R) license to Genuine Health Inc. ("Genuine
Health") for a cardiovascular health product in Canada and the
USA.
Genuine Health (https://www.genuinehealth.com/en-ca/) is an
established Canadian natural health company that has been
formulating natural products for more than 25 years. The company
makes greens+, omegas, proteins and probiotics. Genuine Health's
greens+ is the #1 superfood in Canada and the only superfood to be
validated by nine clinical studies as reported on their website.
The Genuine Health website also states that it specialises in
natural, science based, clinically proven products with ingredients
which create product differentiation in the North American
market.
As part of the agreement, Genuine Health will submit products
containing LP(LDL) (R) for cardiovascular and other health claims
to Health Canada, a department of the Government of Canada
responsible for the country's federal health policy. The Company
believes that if registration is successful LP(LDL) (R) will be the
first probiotic supplement in the Canadian market to obtain a
specific health claim for cardiovascular health.
This agreement is another step in building brand and product
presence in the large North American market as a dietary
supplement, a live biotherapeutic product (LBP), or a functional
ingredient. The agreement is for an initial period of 36
months.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health
commented : "We are pleased to have signed an agreement with
Genuine Health in such a large and important market for probiotic
products. We believe working with Genuine Health creates a unique
opportunity to achieve a probiotic health claim for cardiovascular
health and provide further product differentiation in the North
American market . We see this as another step in b uilding revenues
and mar ket p resence of LP(LDL) (R) inside a wide r a n ge of p
roducts,
presented in different p resentatio ns and form ulation s, for
ca r diovascular health in both consumer and pharmaceutical markets
a round t he w o rld."
Stewart Brown, Founder and CEO of at Genuine Health , c o
mmented: "We are excited to work towards introducing innovative and
science-backed products into the North American market through our
relationship with ProBiotix. The ProBiotix team continue to produce
cutting edge research surrounding the link between probiotics (
LP(LDL) (R) ) and cardiovascular health. This makes them a great
partner in our mission to create products that promote whole-body
health and wellness, with a particular focus on the powerful role
of the microbiome. We look forward to a long and successful
partnership with ProBiotix Health."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the
content of this announcement
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDDLFFBFLBFBL
(END) Dow Jones Newswires
November 18, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
